Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Destiny Pharma's share price is gaining on Wednesday following positive with its lead clinical programme, NTCD-M3.
NTCD-M3 is a novel microbiome therapeutic being developed by Destiny to reduce the recurrence of C. difficile infections (CDI) in the gut.
The company said it feels the microbiome therapeutic has the potential to become the leading treatment for CDI “as it appears to deliver clear advantages to both existing CDI treatment options and also to those currently in clinical development.”
They are currently planning for the single Phase 3 clinical study that needs to be completed before submitting marketing authorisation applications in the US and Europe. The Phase 3 clinical study remains on schedule to commence in 2022.
The London listed company has also begun discussions with potential licensing partners and collaborators and is encouraged by the level of interest in the programme.
Neil Clark, Chief Executive Officer of Destiny Pharma, commented: “We have made significant progress since closing the £10.4 million equity funding in December 2020 that enabled the NTCD-M3 acquisition.
“NTCD-M3 is a potential breakthrough in CDI treatment targeting a market that is forecast to grow to $1.7 billion by 2026 and is a very valuable, late-stage asset. We look forward to making further progress this year and to finalising the Phase 3 study design and manufacturing set up.”
Shortly after the open in London, Destiny Pharma's share price rose 15p to 161.50p. It is currently sitting at 149.26p, up 1.71%.
Destiny Pharma shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Destiny Pharma shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .